Does the media favor CGTX or ENTA?

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat Enanta Pharmaceuticals' score of 0.15 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CGTX or BIOA?

In the previous week, BioAge Labs had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat BioAge Labs' score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CGTX or VNDA?

In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Cognition Therapeutics. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat Vanda Pharmaceuticals' score of 0.46 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IKT or CGTX more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Cognition Therapeutics N/A -50.17% -40.22%

Does the media prefer IKT or CGTX?

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Cognition Therapeutics' average media sentiment score of 0.66 beat Inhibikase Therapeutics' score of 0.34 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cognition Therapeutics (CGTX) Competitors

$0.93 +0.03 (+3.80%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+1.07%)

As of 10/2/2026 07:30 PM Eastern

Compare

CGTX vs. ENTA, BIOA, EYPT, VNDA, and IKT

Should you buy Cognition Therapeutics stock or one of its competitors? Cognition Therapeutics's main competitors and comparable companies include Enanta Pharmaceuticals (ENTA), BioAge Labs (BIOA), Eyepoint Pharmaceuticals (EYPT), Vanda Pharmaceuticals (VNDA), and Inhibikase Therapeutics (IKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Cognition Therapeutics (NASDAQ:CGTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Cognition Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cognition Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Cognition Therapeutics' return on equity of -50.17% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 260.32%. Enanta Pharmaceuticals has a consensus price target of $19.00, indicating a potential upside of 46.60%. Given Cognition Therapeutics' higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Enanta Pharmaceuticals	$65.32M	5.78	-$81.89M	-$2.41	N/A

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat Enanta Pharmaceuticals' score of 0.15 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cognition Therapeutics beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to BioAge Labs?

Cognition Therapeutics (NASDAQ:CGTX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Cognition Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 260.32%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 453.27%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Cognition Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
BioAge Labs	-912.26%	-28.99%	-27.09%

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cognition Therapeutics has higher earnings, but lower revenue than BioAge Labs. Cognition Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
BioAge Labs	$8.99M	33.75	-$80.61M	-$2.38	N/A

In the previous week, BioAge Labs had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat BioAge Labs' score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioAge Labs beats Cognition Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat Eyepoint Pharmaceuticals' score of 0.34 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, indicating a potential upside of 690.77%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 260.32%. Given Eyepoint Pharmaceuticals' higher possible upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Cognition Therapeutics' return on equity of -50.17% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Cognition Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.93	-$231.96M	-$3.74	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Summary

Cognition Therapeutics beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Cognition Therapeutics (NASDAQ:CGTX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Cognition Therapeutics. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.66 beat Vanda Pharmaceuticals' score of 0.46 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cognition Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 260.32%. Vanda Pharmaceuticals has a consensus price target of $13.08, suggesting a potential upside of 182.58%. Given Cognition Therapeutics' higher possible upside, equities analysts clearly believe Cognition Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Cognition Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cognition Therapeutics has higher earnings, but lower revenue than Vanda Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Vanda Pharmaceuticals	$216.10M	1.30	-$220.47M	-$4.63	N/A

Summary

Vanda Pharmaceuticals beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Inhibikase Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 170.00%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 260.32%. Given Cognition Therapeutics' higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Cognition Therapeutics	N/A	-50.17%	-40.22%

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Cognition Therapeutics' average media sentiment score of 0.66 beat Inhibikase Therapeutics' score of 0.34 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Summary

Cognition Therapeutics beats Inhibikase Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$87.97M	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.33%
P/E Ratio	-5.44	799.70	275.67	26.04
Price / Sales	N/A	938.84	656.66	110.58
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	2.37	10.46	10.93	6.31
Net Income	-$23.49M	$2.84B	$3.51B	$362.16M
7 Day Performance	-1.22%	-1.56%	-2.00%	-1.66%
1 Month Performance	-10.18%	-5.58%	-6.19%	-4.68%
1 Year Performance	-40.32%	-2.40%	8.03%	1.57%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	2.2702 of 5 stars	$0.93 +3.8%	$3.33 +260.3%	-40.3%	$87.97M	N/A	N/A	14	Gap Up
ENTA Enanta Pharmaceuticals	1.7598 of 5 stars	$11.88 -1.0%	$21.00 +76.8%	+25.5%	$346.01M	$65.32M	N/A	120	News Coverage Analyst Upgrade Gap Down
BIOA BioAge Labs	3.0594 of 5 stars	$7.05 -2.2%	$36.57 +418.7%	+17.8%	$323.57M	$8.99M	N/A	62	News Coverage
EYPT Eyepoint Pharmaceuticals	2.8604 of 5 stars	$3.62 -0.8%	$25.70 +609.9%	-76.3%	$312.09M	$31.37M	N/A	214	Gap Up
VNDA Vanda Pharmaceuticals	2.7668 of 5 stars	$5.05 +1.4%	$13.08 +159.1%	-14.7%	$305.34M	$216.10M	N/A	533	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. ENTA, BIOA, EYPT, VNDA, and IKT

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to BioAge Labs?

Summary

How does Cognition Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. ENTA, BIOA, EYPT, VNDA, and IKT

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Which has more volatility and risk, CGTX or ENTA?

Do institutionals & insiders believe in CGTX or ENTA?

Is CGTX or ENTA more profitable?

Do analysts recommend CGTX or ENTA?

Which has better valuation and earnings, CGTX or ENTA?

Does the media favor CGTX or ENTA?

Summary

How does Cognition Therapeutics compare to BioAge Labs?

Which has more risk and volatility, CGTX or BIOA?

Do analysts rate CGTX or BIOA?

Is CGTX or BIOA more profitable?

Do institutionals and insiders hold more shares of CGTX or BIOA?

Which has stronger earnings and valuation, CGTX or BIOA?

Does the media favor CGTX or BIOA?

Summary

How does Cognition Therapeutics compare to Eyepoint Pharmaceuticals?

Does the media refer more to EYPT or CGTX?

Do analysts prefer EYPT or CGTX?

Do insiders & institutionals believe in EYPT or CGTX?

Which has more volatility and risk, EYPT or CGTX?

Is EYPT or CGTX more profitable?

Which has better valuation and earnings, EYPT or CGTX?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Does the media prefer CGTX or VNDA?

Which has more risk and volatility, CGTX or VNDA?

Do analysts rate CGTX or VNDA?

Is CGTX or VNDA more profitable?

Do insiders & institutionals hold more shares of CGTX or VNDA?

Which has preferable earnings & valuation, CGTX or VNDA?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Which has more risk and volatility, IKT or CGTX?

Do analysts prefer IKT or CGTX?

Do institutionals & insiders believe in IKT or CGTX?

Is IKT or CGTX more profitable?

Does the media prefer IKT or CGTX?

Which has stronger valuation & earnings, IKT or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools